metformin and mevalonic acid

metformin has been researched along with mevalonic acid in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (33.33)	24.3611
2020's	2 (66.67)	2.80

Authors

Authors	Studies
Fritz, G; Huelsenbeck, J; Nilsson, S	1
Anghel, R; Forsea, L; Gales, L; Georgescu, M; Mitrea, D; Mitrica, R; Serbanescu, L; Stanculescu, I; Stefanica, I; Trifanescu, O	1
Chen, Y; Li, M; Li, X; Lu, Y; Yang, Y	1

Reviews

1 review(s) available for metformin and mevalonic acid

Article	Year
Antidiabetics, Anthelmintics, Statins, and Beta-Blockers as Co-Adjuvant Drugs in Cancer Therapy. Medicina (Kaunas, Lithuania), 2022, Sep-07, Volume: 58, Issue:9 Topics: Adenosine Monophosphate; Adrenergic beta-Antagonists; Anthelmintics; Anti-Bacterial Agents; Antihypertensive Agents; Antimalarials; Antineoplastic Agents; Atorvastatin; Breast Neoplasms; Cholesterol; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Mebendazole; Metformin; Mevalonic Acid; Propranolol; Protein Kinases; Proto-Oncogene Proteins B-raf; Receptors, Adrenergic, beta-2; Tyrosine	2022

Article

Year

Antidiabetics, Anthelmintics, Statins, and Beta-Blockers as Co-Adjuvant Drugs in Cancer Therapy.

Medicina (Kaunas, Lithuania), 2022, Sep-07, Volume: 58, Issue:9

Topics: Adenosine Monophosphate; Adrenergic beta-Antagonists; Anthelmintics; Anti-Bacterial Agents; Antihypertensive Agents; Antimalarials; Antineoplastic Agents; Atorvastatin; Breast Neoplasms; Cholesterol; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Mebendazole; Metformin; Mevalonic Acid; Propranolol; Protein Kinases; Proto-Oncogene Proteins B-raf; Receptors, Adrenergic, beta-2; Tyrosine

2022

Other Studies

2 other study(ies) available for metformin and mevalonic acid

Article	Year
Mevalonate pathway inhibitors affect anticancer drug-induced cell death and DNA damage response of human sarcoma cells. Cancer letters, 2011, May-01, Volume: 304, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Bone Neoplasms; Cell Cycle; Cell Proliferation; Cisplatin; Diphosphonates; DNA Damage; Doxorubicin; Fibrosarcoma; Humans; Lovastatin; Metformin; Mevalonic Acid; Osteosarcoma; Phosphorylation; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured; Tumor Suppressor Protein p53	2011
Antidiabetic drug metformin suppresses tumorigenesis through inhibition of mevalonate pathway enzyme HMGCS1. The Journal of biological chemistry, 2022, Volume: 298, Issue:12 Topics: Cell Line, Tumor; Cell Transformation, Neoplastic; Humans; Hydroxymethylglutaryl-CoA Synthase; Hypoglycemic Agents; Metformin; Mevalonic Acid; NF-E2-Related Factor 2	2022

Article

Year

Mevalonate pathway inhibitors affect anticancer drug-induced cell death and DNA damage response of human sarcoma cells.

Cancer letters, 2011, May-01, Volume: 304, Issue:1

Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Bone Neoplasms; Cell Cycle; Cell Proliferation; Cisplatin; Diphosphonates; DNA Damage; Doxorubicin; Fibrosarcoma; Humans; Lovastatin; Metformin; Mevalonic Acid; Osteosarcoma; Phosphorylation; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured; Tumor Suppressor Protein p53

2011

Antidiabetic drug metformin suppresses tumorigenesis through inhibition of mevalonate pathway enzyme HMGCS1.

The Journal of biological chemistry, 2022, Volume: 298, Issue:12

Topics: Cell Line, Tumor; Cell Transformation, Neoplastic; Humans; Hydroxymethylglutaryl-CoA Synthase; Hypoglycemic Agents; Metformin; Mevalonic Acid; NF-E2-Related Factor 2

2022